Cheang, Maggie Chon U
Rimawi, Mothaffar http://orcid.org/0000-0002-4284-5656
Johnston, Stephen
Jacobs, Samuel A.
Bliss, Judith
Pogue-Geile, Katherine
Kilburn, Lucy
Zhu, Zhou
Schuster, Eugene F.
Xiao, Hui
Swaim, Lisa
Deng, Shibing
Lu, Dongrui R.
Gauthier, Eric http://orcid.org/0000-0002-0160-7571
Tursi, Jennifer
Slamon, Dennis J.
Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Finn, Richard S. http://orcid.org/0000-0003-2494-2126
Liu, Yuan
Funding for this research was provided by:
Pfizer
Article History
Received: 2 August 2023
Accepted: 14 June 2024
First Online: 29 June 2024
Change Date: 26 July 2024
Change Type: Update
Change Details: In this article the author name Maggie Chon U Cheang was incorrectly written as Maggie Chon U. Cheang.
Competing interests
: M.C.U.C. reports royalties and intellectual property rights/patent holder as a coinventor of PAM50 Bioclassifier, consulting fees for Veracyte, and research funding from NanoString Technologies. M.R. reports consulting fees from Macrogenics, Seagen, AstraZeneca, and Novartis, and research funding from Pfizer. S.A.J. reports consulting fees from Eli Lilly, Novartis, Pfizer, and Eisai, fees for non-CME services from AstraZeneca and Eisai, and contracted research from Eli Lilly, Pfizer, and AstraZeneca. J.B. reports research grants from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, Roche, and Eli Lilly. D.J.S. has served as a consultant/advisor for Pfizer Inc, Eli Lilly, and Novartis, has received research funding from Pfizer Inc and Seagen, has received consulting fees from Pfizer Inc and Novartis and travel support from Pfizer Inc and Novartis, participated on a data safety monitoring board or advisory board for Eli Lilly and Novartis, is a board member of BioMarin, and is a stockholder in Amgen, BioMarin, 1200 Pharma, Merck, Pfizer Inc, Seagen, Vertex, and TORL Biotherapeutics. H.S.R. reports sponsored research to her institution from Pfizer Inc, Merck, Novartis, Eli Lilly, Roche, Daiichi-Sankyo, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala, and Gilead and honoraria from PUMA, Samsung, and Mylan. R.S.F. has received consulting fees from Pfizer, Bayer, Novartis, Bristol Myers Squibb, and Merck, as well as other research funding from Pfizer, and honoraria from Bayer, Pfizer, Bristol Myers Squibb, Novartis, Eisai, and Eli Lilly. L.S., S.D., D.R.L., E.G., and Y.L. are employees of and stockholders in Pfizer Inc. Z.Z. and J.T. are former employees of and own stock in Pfizer Inc. S.A.J., K.P.-G., L.K., E.F.S., and H.X. have no competing interests.